Status:
COMPLETED
A Long-term Extension Study Evaluating a One-Month Dosing Regimen of Degarelix in Prostate Cancer Requiring Androgen Ablation Therapy
Lead Sponsor:
Ferring Pharmaceuticals
Conditions:
Prostate Cancer
Eligibility:
MALE
18+ years
Phase:
PHASE3
Brief Summary
Participants who completed the FE200486 CS21 study (NCT00295750) could enter the FE200486 CS21A study. The study continued until all non-discontinued participants had received treatment for at least 5...
Eligibility Criteria
Inclusion
- Inclusion/Exclusion Criteria:
- Patients with histologically proven prostate cancer of all stages in whom endocrine treatment is indicated.
- Signed informed consent
- The patients must have completed the FE 200486 CS21 Study.
Exclusion
Key Trial Info
Start Date :
March 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2011
Estimated Enrollment :
386 Patients enrolled
Trial Details
Trial ID
NCT00451958
Start Date
March 1 2007
End Date
December 1 2011
Last Update
March 21 2013
Active Locations (69)
Enter a location and click search to find clinical trials sorted by distance.
1
Urology Centers Of Alabama
Homewood, Alabama, United States
2
South Orange County Medical Research Center
Laguna Hills, California, United States
3
Western Clinical Research
Torrance, California, United States
4
Urology Associates Research
Englewood, Colorado, United States